Drug class in one race
PD-1 drugs for Non-Small Cell Lung Cancer
23 tracked PD-1 drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the PD-1 page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
5 approved / phase 411 Phase 32 Phase 2/31 Phase 23 Phase 1/21 preclinical / unstaged
Head-to-head evidence: Abp 234 vs Camrelizumab · Abp 234 vs Cemiplimab · Abp 234 vs Dostarlimab · Abp 234 vs MB12 · Abp 234 vs Nivolumab · Abp 234 vs Pembrolizumab